Business Context and Reporting Period
This Form 8-K, dated March 5, 2024, is filed by Graphite Bio, Inc. (GRPH) regarding its proposed merger with LENZ Therapeutics, Inc. (LENZ). The filing serves as a supplemental disclosure to the previously filed Proxy Statement/Prospectus (Form S-4) to address allegations made in two shareholder lawsuits and twelve demand letters. The lawsuits allege misrepresentations regarding LENZ's financial projections, advisor conflicts, and Graphite's liquidation analysis. Graphite denies these allegations but voluntarily provided additional details to moot disclosure claims and avoid delays.
Key Financial Metrics and Transaction Details
- Transaction Structure: Merger Sub (a Graphite subsidiary) will merge with LENZ, with LENZ surviving as a wholly-owned subsidiary of Graphite.
- LENZ Valuation (DCF Analysis): Leerink Partners LLC estimated LENZ's implied equity value at approximately $460 million to $540 million based on a discounted cash flow analysis using a discount rate of 11% to 13%.
- LENZ Cash Position: LENZ had an estimated net cash balance of $57.3 million as of January 31, 2024.
- Graphite Liquidation Analysis:
- Immediate Distribution: Estimated $166.8 million available for distribution in February 2024, equating to approximately $2.86 per share (based on ~58 million fully diluted shares).
- Long-term Liquidation: Estimated remaining net cash distribution in March 2027 ranges from $5.6 million (low case) to $11.1 million (high case), or $0.10 to $0.19 per share.
- Transaction Costs (Wind-down): Includes approximately $750,000 in legal fees, $1.5 million in strategic advisor fees, $1.7 million in accounting fees, $1.9 million in employee retention bonuses, and $5 million in insurance/other costs.
Material Changes and Supplemental Disclosures
The filing amends the Proxy Statement/Prospectus with the following specific clarifications:
- Transaction Committee: Clarified that the committee was established on January 27, 2023, to explore strategic alternatives. Members received no additional compensation. The committee met weekly and in executive sessions without management present.
- Financial Advisor Conflicts: Leerink Partners LLC has not provided investment banking services to or received compensation from LENZ in the past two years. It has provided services to Graphite in the past but received no compensation in the last two years. Leerink may hold positions in securities of either company in the ordinary course of business.
- DCF Assumptions: The valuation model assumes a 50% annual decline in cash flows after 2036 in perpetuity, as provided by Graphite management.
- Post-Merger Management: As of February 29, 2024, no Graphite executive officers are expected to serve as executive officers of the combined company. Kimberlee C. Drapkin will serve as a non-employee director.
Guidance, Risks, and Contingencies
Litigation Risks: Two complaints have been filed (Northern District of California and District of Delaware) seeking to enjoin the merger or award rescissory damages. Graphite intends to vigorously defend against these claims. Additional lawsuits or demand letters may arise before the merger closes.
Forward-Looking Risks: The filing highlights significant uncertainties, including:
- Failure to obtain stockholder approval or regulatory approvals.
- Delays in the consummation of the merger or the concurrent private financing.
- Uncertainties regarding LENZ's product candidates, clinical trial timelines, and regulatory approvals.
- Potential inability of the combined company to secure sufficient capital to advance product development.
- Market price volatility of Graphite stock relative to the exchange ratio.
Management Commentary: Graphite asserts that the original disclosures complied with all applicable laws and denies the necessity of the supplemental disclosures as an admission of legal merit. The supplements are provided solely to facilitate the transaction and provide additional information to stockholders.
Investor Verification Checklist
- Verify the status of the two pending shareholder lawsuits (Glen Chew v. Graphite Bio and Kevin Turner v. Graphite Bio) and any potential injunctions.
- Confirm the final exchange ratio and the implied equity value of LENZ relative to the $460M-$540M DCF range provided.
- Review the terms of the concurrent private financing mentioned in the forward-looking statements to assess post-merger liquidity.
- Monitor the timeline for the stockholder vote and the expected closing date of the merger.
- Assess the clinical development pipeline and regulatory risks associated with LENZ's product candidates as detailed in the full Proxy Statement/Prospectus.